These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35098540)

  • 41. The Assessment of Convalescent Plasma Efficacy against COVID-19.
    Casadevall A; Grossman BJ; Henderson JP; Joyner MJ; Shoham S; Pirofski LA; Paneth N
    Med; 2020 Dec; 1(1):66-77. PubMed ID: 33363284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
    Joob B; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
    [No Abstract]   [Full Text] [Related]  

  • 43. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):296-298. PubMed ID: 34102319
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole blood derived covid convalescent plasma: A practical experience from India.
    Mandal A; Chakrabarty R; Datta SS
    Transfus Apher Sci; 2021 Aug; 60(4):103140. PubMed ID: 33858755
    [No Abstract]   [Full Text] [Related]  

  • 46. A look-back at convalescent plasma to treat COVID-19.
    Garraud O; Lacombe K; Tiberghien P
    Transfus Apher Sci; 2021 Feb; 60(1):103063. PubMed ID: 33478889
    [No Abstract]   [Full Text] [Related]  

  • 47. Potential mechanisms of action of convalescent plasma in COVID-19.
    Franchini M; Glingani C; Liumbruno GM
    Diagnosis (Berl); 2021 Nov; 8(4):413-420. PubMed ID: 33652503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.
    Estcourt L; Callum J
    N Engl J Med; 2022 May; 386(18):1753-1754. PubMed ID: 35507487
    [No Abstract]   [Full Text] [Related]  

  • 49. Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague.
    Bohoněk M; Řezáč D; Holub M
    Cas Lek Cesk; 2020; 159(5):175-180. PubMed ID: 33297703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Use of convalescent plasma for COVID-19 treatment. History and evidence].
    McAllister F; Mantegazza A; Garzón F; Rotbaum V; Remondino G; Vazquez Larsson M; Geffner J; Rabinovich GA; Bover L
    Medicina (B Aires); 2020; 80 Suppl 3():82-86. PubMed ID: 32658853
    [No Abstract]   [Full Text] [Related]  

  • 52. Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!
    Sanfilippo F; La Rosa V; Oliveri F; Astuto M
    Crit Care; 2020 Aug; 24(1):531. PubMed ID: 32859242
    [No Abstract]   [Full Text] [Related]  

  • 53. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
    Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
    Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
    [No Abstract]   [Full Text] [Related]  

  • 54. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.
    Kesici S; Yavuz S; Bayrakci B
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12526-12527. PubMed ID: 32398378
    [No Abstract]   [Full Text] [Related]  

  • 56. Convalescent plasma, political narrative, and public health ethics in the Covid-19 pandemic.
    Agrawal S; Agarwal A; Jain Y
    Indian J Med Ethics; 2021; VI(3):1-7. PubMed ID: 34287194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Convalescent Plasma in the Management of COVID-19.
    Dandachi D; Khalaf SA
    Mo Med; 2021; 118(2):118. PubMed ID: 33840851
    [No Abstract]   [Full Text] [Related]  

  • 58. Transfusion-related acute lung injury in a COVID-19-positive convalescent plasma recipient: a case report.
    Amrutiya V; Patel R; Baghal M; Patel B; Waykole T; Patel H; Govil S; Lo A
    J Int Med Res; 2021 Aug; 49(8):3000605211032814. PubMed ID: 34412545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma.
    Sanfilippo F; La Rosa V; Oliveri F; Astuto M
    Am J Respir Crit Care Med; 2021 Jan; 203(2):257-258. PubMed ID: 33085908
    [No Abstract]   [Full Text] [Related]  

  • 60. Convalescent plasma for covid-19.
    Estcourt LJ; Roberts DJ
    BMJ; 2020 Sep; 370():m3516. PubMed ID: 32933945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.